DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Epigenomics AG

XTRA:ECX Stock Report

Market Cap: €616.0k

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epigenomics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Noel Doheny

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.2yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4.1yrs

Recent management updates

Recent updates

Analysis Article • Jul 02

A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Epigenomics fair value estimate is €0.99 With €0.88 share...
Analysis Article • Jun 12

We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 15

When Will Epigenomics AG (ETR:ECX) Breakeven?

We feel now is a pretty good time to analyse Epigenomics AG's ( ETR:ECX ) business as it appears the company may be on...

CEO

Noel Doheny

13.2yrs
Tenure

Dr. Noel Thomas Doheny has been the Chief Executive Officer of Epigenomics Inc. at Epigenomics AG since May 2011. Dr. Doheny manages all US activities and global business development and partnership develo...


Board Members

NamePositionTenureCompensationOwnership
Helge Lubenow
Chairman of the Supervisory Board8.2yrs€25.00kno data
Alexander Link
Vice-chairman of Supervisory Board4.1yrs€25.00kno data
Jochen Hummel
Member of Supervisory Boardless than a yearno datano data
4.1yrs
Average Tenure
54yo
Average Age

Experienced Board: ECX's board of directors are considered experienced (4.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/10 05:17
End of Day Share Price 2024/07/10 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Epigenomics AG is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans Bjorn BostromEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Bryan BrokmeierMaxim Group

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide